The biotech IPO feast flags as investors lose their appetite for R&D risk
There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Funds chased each other for huge returns. CEOs became overnight millionaires.
Now the market pendulum has swung back as the bears pushed aside the bulls. But that doesn’t mean that the new ice age has begun, either.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.